


Figure 1

A

Pre-emptive arm



Prophylactic arm



Interim analysis

Cohort 1: CD19CAR CTL alone

Cohort 2: CD19CAR CTL + Vaccination

Primary Endpoints:

Toxicity (grade III/IV NCI, GVHD,
hypogammaglobulinaemia)
Efficacy (BM MRD)

Secondary Endpoints:

Persistence CD19CAR CTL (flow, qPCR)
Relapse rate, DFS, OS (1, 2yrs post-SCT)

B

Lymphodepletion

Fludarabine
30 mg/m²



Cytoreduction

Vincristine
1.5 mg/m²



Dexamethasone
5 mg/m²



Days

-9

-3

-2

+30

+60

LCL vaccination
(5x10⁶)

CD19CAR CTL
infusion
(2x10⁸/m²)

LCL
vaccination

LCL
vaccination